We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons Why Investors Should Consider Betting on PGEN Stock
Read MoreHide Full Article
Key Takeaways
Precigen's Papzimeos generated $53.3 million in Q2 revenues, more than doubling sequentially.
Papzimeos has FDA market exclusivity through August 2032, supporting a durable commercial franchise.
Precigen is advancing PRGN-2009 in phase II studies targeting HPV-associated cancers.
Precigen (PGEN - Free Report) , a commercial-stage company specializing in innovative precision medicines, is making steady progress with strong commercial performance from its sole marketed drug Papzimeos (zopapogene imadenovec-drba). As the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP), Papzimeos provides Precigen with a differentiated commercial position and a potentially durable revenue base.
Year to date, PGEN shares have surged 71.3% compared with the industry’s 7.1% growth.
Image Source: Zacks Investment Research
Papzimeos Is Driving Rapid Revenue Growth
Papzimeos has demonstrated strong early commercial momentum since its launch in August 2025. In the second quarter of 2026, the company recorded product revenues of $53.3 million, more than doubling sequentially. For the first six months of 2026, the product generated $75.1 million of revenues.
Notably, the rapid revenue ramp translated into quarterly profitability, with Precigen reporting $20.1 million in net income in the second quarter compared with a $26.6 million net loss in the year-ago quarter. Rising patient hub enrollment and expanding adoption across major medical centers and community practices indicate that the product is gaining traction beyond the initial launch phase.
Market Exclusivity Provides Revenue Protection for PGEN
Papzimeos benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection gives Precigen an opportunity to establish a durable commercial franchise before potential competitors enter the market.
International Expansion Adds Long-Term Upside for PGEN
Precigen is pursuing additional growth opportunities outside the United States. The company’s marketing authorization application submitted to the European Medicines Agency in November 2025 is currently under review. Approval in Europe could provide another source of revenue growth. A redosing study is also underway, which could expand the product’s long-term treatment opportunity if supported by clinical results.
PRGN-2009 Provides Pipeline Optionality for PGEN
Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. PRGN-2009 is an investigational AdenoVerse immunotherapy being developed to activate the immune system and target HPV-associated cancers. The candidate is currently being evaluated in phase II clinical studies in patients with newly diagnosed HPV-associated oropharyngeal cancer. In parallel, Precigen is conducting a multicenter phase II study evaluating PRGN-2009 in combination with Merck & Co’s (MRK - Free Report) Keytruda (pembrolizumab) in patients with recurrent or metastatic cervical cancer. Keytruda, MRK’s blockbuster drug, is approved for several types of cancers globally.
Although the candidate remains at the clinical stage and carries development risk, its progress could provide an additional source of long-term value and further validate Precigen’s HPV-focused technology. The company plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026.
Precigen currently sports a Zacks Rank #1 (Strong Buy). Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, estimates for earnings per share increased from $1.12 to $1.21 for 2027. AMRX shares have risen 43.7% year to date.
Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.
Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have declined 17.9% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
View the Zacks #1 Rank List
Image: Bigstock
Reasons Why Investors Should Consider Betting on PGEN Stock
Key Takeaways
Precigen (PGEN - Free Report) , a commercial-stage company specializing in innovative precision medicines, is making steady progress with strong commercial performance from its sole marketed drug Papzimeos (zopapogene imadenovec-drba). As the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP), Papzimeos provides Precigen with a differentiated commercial position and a potentially durable revenue base.
Year to date, PGEN shares have surged 71.3% compared with the industry’s 7.1% growth.
Image Source: Zacks Investment Research
Papzimeos Is Driving Rapid Revenue Growth
Papzimeos has demonstrated strong early commercial momentum since its launch in August 2025. In the second quarter of 2026, the company recorded product revenues of $53.3 million, more than doubling sequentially. For the first six months of 2026, the product generated $75.1 million of revenues.
Notably, the rapid revenue ramp translated into quarterly profitability, with Precigen reporting $20.1 million in net income in the second quarter compared with a $26.6 million net loss in the year-ago quarter. Rising patient hub enrollment and expanding adoption across major medical centers and community practices indicate that the product is gaining traction beyond the initial launch phase.
Market Exclusivity Provides Revenue Protection for PGEN
Papzimeos benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection gives Precigen an opportunity to establish a durable commercial franchise before potential competitors enter the market.
International Expansion Adds Long-Term Upside for PGEN
Precigen is pursuing additional growth opportunities outside the United States. The company’s marketing authorization application submitted to the European Medicines Agency in November 2025 is currently under review. Approval in Europe could provide another source of revenue growth. A redosing study is also underway, which could expand the product’s long-term treatment opportunity if supported by clinical results.
PRGN-2009 Provides Pipeline Optionality for PGEN
Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. PRGN-2009 is an investigational AdenoVerse immunotherapy being developed to activate the immune system and target HPV-associated cancers. The candidate is currently being evaluated in phase II clinical studies in patients with newly diagnosed HPV-associated oropharyngeal cancer. In parallel, Precigen is conducting a multicenter phase II study evaluating PRGN-2009 in combination with Merck & Co’s (MRK - Free Report) Keytruda (pembrolizumab) in patients with recurrent or metastatic cervical cancer. Keytruda, MRK’s blockbuster drug, is approved for several types of cancers globally.
Although the candidate remains at the clinical stage and carries development risk, its progress could provide an additional source of long-term value and further validate Precigen’s HPV-focused technology. The company plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026.
Precigen, Inc. Price and Consensus
Precigen, Inc. price-consensus-chart | Precigen, Inc. Quote
PGEN's Zacks Rank & Estimates
Precigen currently sports a Zacks Rank #1 (Strong Buy). Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) , currently sporting a Zacks Rank #1, while AC Immune (ACIU - Free Report) carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, estimates for earnings per share increased from $1.12 to $1.21 for 2027. AMRX shares have risen 43.7% year to date.
Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.
Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have declined 17.9% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.